# Cretostimogene grenadenorepvec

Source: https://onco.cc/drugs/cretostimogene/  
OnCo record `cretostimogene` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cretostimogene is a virus engineered to multiply only in bladder cancer cells with a broken RB pathway, instilled into the bladder. It cleared carcinoma in situ in 75% of BCG-unresponsive patients.

## Summary

Replication restricted by the E2F-1 promoter to RB-deficient cells; expresses GM-CSF. BOND-003 cohort C: CR 75.2%, 24-month CR 41.8%, no grade 3+ treatment-related events. Rolling BLA under way; full submission expected Q4 2026. Also tested in BCG-naive (CORE-008) and intermediate-risk (PIVOT-006) NMIBC. CG Oncology.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-07
- Code: CG0070
- Modality: Oncolytic adenovirus (intravesical)
- Mechanism: Conditionally replicating adenovirus lyses RB-pathway-defective tumour cells and secretes GM-CSF to recruit antigen-presenting cells.
- Dosing: Intravesical; Weekly ×6 induction, re-induction if needed, then maintenance every 3 months up to 3 years
- Toxicity (grade 3+): Grade 3+ treatment-related 0%

## Sources

- ClinicalTrials.gov NCT04452591 (BOND-003): https://clinicaltrials.gov/study/NCT04452591

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Non-muscle-invasive bladder cancer](https://onco.cc/cancers/non-muscle-invasive-bladder-cancer/)
- technologies: [Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)](https://onco.cc/technologies/bcg-and-intravesical-therapy/), [Oncolytic viruses](https://onco.cc/technologies/oncolytic-virus/)
- companies: [CG Oncology](https://onco.cc/companies/cg-oncology/)
- terms: [BCG-unresponsive](https://onco.cc/terms/bcg-unresponsive/)
- trials: [A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT](https://onco.cc/trials/nct06111235/), [BOND-003](https://onco.cc/trials/bond-003/), [Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC](https://onco.cc/trials/nct06567743/), [Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin](https://onco.cc/trials/nct07283835/)
- ideas: [Oncolytic viruses that make interleukin-12 only inside the tumour](https://onco.cc/ideas/idea-bio2-oncolytic-regulated-il12/)

---
JSON: https://onco.cc/api/v1/entities/cretostimogene.json